81272 KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)

Name of the Procedure:

KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) Gene Analysis, Targeted Sequence Analysis (e.g., exons 8, 11, 13, 17, 18)

Summary

KIT gene analysis involves examining specific regions (exons 8, 11, 13, 17, and 18) of the KIT gene to detect mutations. This is particularly useful in diagnosing and guiding the treatment of certain cancers like gastrointestinal stromal tumors (GISTs), acute myeloid leukemia (AML), and melanoma.

Purpose

The KIT gene analysis procedure aims to identify mutations that can drive the growth of certain cancers. Detecting these mutations helps tailor treatment plans, improve patient outcomes, and determine eligibility for targeted therapies.

Indications

• Diagnosed or suspected gastrointestinal stromal tumors (GISTs)
• Acute myeloid leukemia (AML)
• Melanoma
• Unexplained symptoms or clinical presentations suggestive of these cancers
• Patients who might benefit from targeted therapies based on KIT gene mutations

Preparation

• No specific fasting or major preparation required.
• Routine blood work or imaging tests might be performed to assess overall health and suitability for the procedure.

Procedure Description

1. A blood sample is drawn from the patient.
2. The DNA is extracted from the sample in a laboratory setting.
3. Targeted sequencing is performed on exons 8, 11, 13, 17, and 18 of the KIT gene to identify mutations.
4. The results are analyzed and interpreted by a geneticist or oncologist.
5. Findings are discussed with the patient to guide treatment decisions.

Duration

The procedure to draw the blood takes a few minutes, while the genetic analysis process might take several days to a couple of weeks, depending on the laboratory’s workload and technology used.

Setting

• The blood sample can be collected in an outpatient clinic or hospital setting.
• The genetic analysis is conducted in a specialized laboratory.

Personnel

• Phlebotomist or nurse to draw the blood sample.
• Medical geneticist, molecular pathologist, or oncologist to analyze and interpret the results.

Risks and Complications

• Minimal risks involved with standard blood draw, such as minor bruising or discomfort at the puncture site.
• Rarely, emotional distress upon receiving genetic findings that indicate a high risk of cancer.

Benefits

• Identification of specific genetic mutations allows for targeted and personalized treatment plans.
• Helps in predicting prognosis and tailoring follow-up care.
• May provide eligibility for clinical trials or specific therapies.

Recovery

• No significant recovery time is needed.
• Patients can resume normal activities immediately after the blood draw.
• Follow-up appointments will be needed to discuss the genetic analysis results and treatment options.

Alternatives

• Other genetic tests or broader genomic sequencing might be considered based on clinical discretion.
• Standard chemotherapy or radiation treatments without specific genetic guidance.
• Pros and cons depend on individual patient scenarios and the potential effectiveness of different treatments.

Patient Experience

• Minimal discomfort during the blood draw.
• No pain associated with the genetic analysis as it is performed on the extracted DNA.
• Anxiety or stress might occur while waiting for or upon receiving results, hence support from healthcare professionals is crucial.